Aptose Biosciences (NASDAQ:APTO) Rating Lowered to Sell at StockNews.com

Aptose Biosciences (NASDAQ:APTOGet Free Report) (TSE:APS) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Monday.

A number of other research analysts have also recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Aptose Biosciences in a research report on Wednesday, March 27th. Piper Sandler reissued an “overweight” rating and issued a $5.00 price target on shares of Aptose Biosciences in a research note on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to MarketBeat, Aptose Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.80.

Get Our Latest Report on APTO

Aptose Biosciences Stock Performance

Aptose Biosciences stock opened at $1.23 on Monday. Aptose Biosciences has a fifty-two week low of $1.15 and a fifty-two week high of $7.74. The stock has a market cap of $20.04 million, a P/E ratio of -0.16 and a beta of 1.36. The firm’s fifty day moving average price is $1.39 and its 200-day moving average price is $1.99.

Aptose Biosciences (NASDAQ:APTOGet Free Report) (TSE:APS) last issued its quarterly earnings results on Tuesday, March 26th. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.48) by $0.04. On average, analysts predict that Aptose Biosciences will post -3.31 earnings per share for the current year.

Hedge Funds Weigh In On Aptose Biosciences

Hedge funds have recently modified their holdings of the company. Annandale Capital LLC grew its stake in shares of Aptose Biosciences by 40.0% in the third quarter. Annandale Capital LLC now owns 74,666 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 21,334 shares during the last quarter. Sigma Planning Corp bought a new stake in shares of Aptose Biosciences in the 3rd quarter worth approximately $408,000. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Aptose Biosciences during the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

(Get Free Report)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Read More

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.